Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3282262 | Clinical Gastroenterology and Hepatology | 2015 | 12 Pages |
Abstract
In a chemoprevention trial of patients with BE, daily administration of metformin for 12 weeks, compared with placebo, did not cause major reductions in esophageal levels of pS6K1. Although metformin reduced serum levels of insulin and insulin resistance, it did not discernibly alter epithelial proliferation or apoptosis in esophageal tissues. These findings do not support metformin as a chemopreventive agent for BE-associated carcinogenesis. ClinicalTrials.gov number, NCT01447927.
Keywords
AMPKIGFBPIGFEACAMPNSAIDmTORHOMA-IRIGF-1REGDadenosine monophosphate–activated protein kinaseadenosine monophosphateEsophageal adenocarcinomaesophagogastroduodenoscopyCancer developmentTumorigenesisnonsteroidal anti-inflammatory drugbody mass indexBMIadverse eventInsulin-like growth factorHomeostatic model of insulin resistanceBarrett’s esophagusmammalian target of rapamycininsulin-like growth factor binding proteininsulin receptorInsulin-like growth factor-1 receptor
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Amitabh Chak, Navtej S. Buttar, Nathan R. Foster, Drew K. Seisler, Norman E. Marcon, Robert Schoen, Marcia R. Cruz-Correa, Gary W. Falk, Prateek Sharma, Chin Hur, David A. Katzka, Luz M. Rodriguez, Ellen Richmond, Anamay N. Sharma, Thomas C. Smyrk,